Receptor tyrosine kinases: Characterisation, mechanism of action and therapeutic interests for bone cancers

Activating Mutations in the Epidermal Growth Factor Receptor Underlying Responsiveness of Non–Small-Cell Lung Cancer to Gefitinib

Lynch, T. J., Bell, D. W., Sordella, R., Gurubhagavatula, S., Okimoto, R. A., Brannigan, B. W., Harris, P. L., Haserlat, S. M., Supko, J. G., Haluska, F. G., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa040938 · Cited by 11,486 · see citing works

Cell Signaling by Receptor Tyrosine Kinases

Lemmon, M. A., & Schlessinger, J. (2010) · Cell · doi:10.1016/j.cell.2010.06.011 · Cited by 7,929 · see citing works

Oncogenic kinase signalling.

Blume-Jensen, P., & Hunter, T. (2001) · Nature · doi:10.1038/35077225 · Cited by 3,738 · see citing works

Activation and function of the MAPKs and their substrates, the MAPK-activated protein kinases

Cargnello, M., & Roux, P. P. (2011) · Microbiology and Molecular Biology Reviews · doi:10.1128/mmbr.00031-10 · Cited by 3,274 · see citing works

Met, metastasis, motility and more

Birchmeier, C., Birchmeier, W., Gherardi, E., & Woude, G. V. (2003) · Nature reviews. Molecular cell biology · doi:10.1038/nrm1261 · Cited by 2,667 · see citing works

The activation of Akt/PKB signaling pathway and cell survival

Song, G., Ouyang, G., & Bao, S. (2005) · Journal of Cellular and Molecular Medicine · doi:10.1111/j.1582-4934.2005.tb00337.x · Cited by 1,891 · see citing works

ERK1/2 MAP kinases: Structure, function, and regulation

Roskoski, R. J. (2012) · Pharmacological Research · doi:10.1016/j.phrs.2012.04.005 · Cited by 1,642 · see citing works

Differential regulation and properties of MAPKs

Raman, M., Chen, W., & Cobb, M. H. (2007) · Oncogene · doi:10.1038/sj.onc.1210392 · Cited by 1,430 · see citing works

MET signalling: principles and functions in development, organ regeneration and cancer

Trusolino, L., Bertotti, A., & Comoglio, P. M. (2010) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm3012 · Cited by 1,244 · see citing works

Crystal Structure of the Complex of Human Epidermal Growth Factor and Receptor Extracellular Domains

Ogiso, H., Ishitani, R., Nureki, O., Fukai, S., Yamanaka, M., Kim, J.-H., Saito, K., Sakamoto, A., Inoue, M., Shirouzu, M., et al. (2002) · Cell · doi:10.1016/s0092-8674(02)00963-7 · Cited by 1,227 · see citing works

The protein tyrosine kinase family of the human genome

Robinson, D. R., Wu, Y., & Lin, S. (2000) · Oncogene · doi:10.1038/sj.onc.1203957 · Cited by 1,179 · see citing works

Protein Tyrosine Kinase Structure and Function

Hubbard, S. R., & Till, J. H. (2000) · Annual Review of Biochemistry · doi:10.1146/annurev.biochem.69.1.373 · Cited by 1,176 · see citing works

Activating HER2 Mutations in HER2 Gene Amplification Negative Breast Cancer

Bose, R., Kavuri, S. M., Searleman, A. C., Shen, W., Shen, D., Koboldt, D. C., Monsey, J. D., Goel, N. J., Aronson, A. B., Li, S., et al. (2012) · Cancer Discovery · doi:10.1158/2159-8290.cd-12-0349 · Cited by 869 · see citing works

IL-2 family cytokines: new insights into the complex roles of IL-2 as a broad regulator of T helper cell differentiation

Liao, W., Lin, J., & Leonard, W. J. (2011) · Current Opinion in Immunology · doi:10.1016/j.coi.2011.08.003 · Cited by 744 · see citing works

Coupling the activities of bone formation and resorption: a multitude of signals within the basic multicellular unit

Sims, N. A., & Martin, T. J. (2014) · BoneKEy Reports · doi:10.1038/bonekey.2013.215 · Cited by 710 · see citing works

c-Src-mediated Phosphorylation of the Epidermal Growth Factor Receptor on Tyr845 and Tyr1101 Is Associated with Modulation of Receptor Function

Biscardi, J. S., Maa, M.-C., Tice, D. A., Cox, M. E., Leu, T.-H., & Parsons, S. J. (1999) · Journal of Biological Chemistry · doi:10.1074/jbc.274.12.8335 · Cited by 649 · see citing works

Growth factor-induced MAPK network topology shapes Erk response determining PC-12 cell fate

Santos, S. D. M., Verveer, P. J., & Bastiaens, P. I. H. (2007) · Nature Cell Biology · doi:10.1038/ncb1543 · Cited by 609 · see citing works

Decoding signalling networks by mass spectrometry-based proteomics

Choudhary, C., & Mann, M. (2010) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm2900 · Cited by 575 · see citing works

Receptor tyrosine kinases: mechanisms of activation and signaling

Hubbard, S. R., & Miller, W. T. (2007) · Current Opinion in Cell Biology · doi:10.1016/j.ceb.2007.02.010 · Cited by 535 · see citing works

Feedback control of intercellular signalling in development

Freeman, M. (2000) · Nature · doi:10.1038/35042500 · Cited by 534 · see citing works

The Bone Marrow Microenvironment as a Tumor Sanctuary and Contributor to Drug Resistance

Meads, M. B., Hazlehurst, L., & Dalton, W. S. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-2223 · Cited by 519 · see citing works

A module of negative feedback regulators defines growth factor signaling

Amit, I., Citri, A., Shay, T., Lu, Y., Katz, M., Zhang, F., Tarcic, G., Siwak, D. R., Lahad, J. P., Jacob‐Hirsch, J., et al. (2007) · Nature Genetics · doi:10.1038/ng1987 · Cited by 488 · see citing works

The interplay between Src family kinases and receptor tyrosine kinases

Bromann, P. A., Körkaya, H., & Courtneidge, S. A. (2004) · Oncogene · doi:10.1038/sj.onc.1208079 · Cited by 451 · see citing works

Cabozantinib in Patients With Advanced Prostate Cancer: Results of a Phase II Randomized Discontinuation Trial

Smith, D. C., Smith, M. R., Sweeney, C. J., Elfiky, A. A., Logothetis, C. J., Corn, P. G., Vogelzang, N. J., Small, E. J., Harzstark, A. L., Gordon, M. S., et al. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2012.45.0494 · Cited by 446 · see citing works

VEGF: an Essential Mediator of Both Angiogenesis and Endochondral Ossification

Dai, J., & Rabie, A. B. M. (2007) · Journal of Dental Research · doi:10.1177/154405910708601006 · Cited by 403 · see citing works

Role of protein ubiquitylation in regulating endocytosis of receptor tyrosine kinases

Marmor, M. D., & Yarden, Y. (2004) · Oncogene · doi:10.1038/sj.onc.1207390 · Cited by 382 · see citing works

Integrin-induced Epidermal Growth Factor (EGF) Receptor Activation Requires c-Src and p130Cas and Leads to Phosphorylation of Specific EGF Receptor Tyrosines

Moro, L., Dolce, L., Cabodi, S., Bergatto, E., Erba, E. B., Smeriglio, M., Turco, E., Retta, S. F., Giuffrida, M. G., Venturino, M., et al. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m109101200 · Cited by 378 · see citing works

A phase II trial of sorafenib in relapsed and unresectable high-grade osteosarcoma after failure of standard multimodal therapy: an Italian Sarcoma Group study

Grignani, G., Palmerini, E., Dileo, P., Asaftei, S. D., D’Ambrosio, L., Pignochino, Y., Mercuri, M., Picci, P., Fagioli, F., Casali, P. G., et al. (2012) · Annals of Oncology · doi:10.1093/annonc/mdr151 · Cited by 359 · see citing works

Negative receptor signalling.

Dikič, I., & Giordano, S. (2003) · Current Opinion in Cell Biology · doi:10.1016/s0955-0674(03)00004-8 · Cited by 342 · see citing works

Activation of preformed EGF receptor dimers by ligand-induced rotation of the transmembrane domain11Edited by B. Holland

Moriki, T., Maruyama, H., & MARUYAMA, I. N. (2001) · Journal of Molecular Biology · doi:10.1006/jmbi.2001.4923 · Cited by 337 · see citing works

Hepatocyte growth factor and its receptor (c-MET) in prostatic carcinoma.

Humphrey, P. A., Zhu, X., Zarnegar, R., et al. (1995) · PubMed · Cited by 332 · see citing works

Epidermal Growth Factor-Induced Tumor Cell Invasion and Metastasis Initiated by Dephosphorylation and Downregulation of Focal Adhesion Kinase

Lu, Z., Jiang, G., Blume‐Jensen, P., & Hunter, T. R. (2001) · Molecular and Cellular Biology · doi:10.1128/mcb.21.12.4016-4031.2001 · Cited by 330 · see citing works

Grb2 Regulates Internalization of EGF Receptors through Clathrin-coated Pits

Jiang, X., Huang, F., Marusyk, A., & Sorkin, A. D. (2003) · Molecular Biology of the Cell · doi:10.1091/mbc.e02-08-0532 · Cited by 322 · see citing works

Effects of Blocking Platelet-Derived Growth Factor-Receptor Signaling in a Mouse Model of Experimental Prostate Cancer Bone Metastases

Uehara, H., Kim, S. J., Karashima, T., Shepherd, D. L., Fan, D., Tsan, R., Killion, J. J., Logothetis, C. J., Mathew, P. F., & Fidler, I. J. (2003) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/95.6.458 · Cited by 280 · see citing works

C-met Proto-Oncogene Expression in Benign and Malignant Human Prostate Tissues

Pisters, L. L., Troncoso, P., Zhau, H. E., Li, W., von Eschenbach, A. C., & Chung, L. W. K. (1995) · The Journal of Urology · doi:10.1016/s0022-5347(01)67297-5 · Cited by 269 · see citing works

Coexpression of hepatocyte growth factor and receptor (Met) in human breast carcinoma.

Tuck, A. B., Park, M., Sterns, E. E., Boag, A., & Elliott, B. E. (1996) · Europe PMC (PubMed Central) · Cited by 244 · see citing works

Phase II Trial of Trastuzumab in Combination With Cytotoxic Chemotherapy for Treatment of Metastatic Osteosarcoma With Human Epidermal Growth Factor Receptor 2 Overexpression: A Report From the Children's Oncology Group

Ebb, D., Meyers, P., Grier, H., Bernstein, M., Gorlick, R., Lipshultz, S. E., Krailo, M., Devidas, M., Barkauskas, D. A., Siegal, G. P., et al. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2011.37.4546 · Cited by 243 · see citing works

Phase II Multicenter Trial of Imatinib in 10 Histologic Subtypes of Sarcoma Using a Bayesian Hierarchical Statistical Model

Chugh, R. K., Wathen, J. K., Maki, R. G., Benjamin, R. S., PATEL, S. R., Myers, P. A., Priebat, D. A., Reinke, D. K., Thomas, D. G., Keohan, M. L., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.20.5054 · Cited by 232 · see citing works

Docetaxel and dasatinib or placebo in men with metastatic castration-resistant prostate cancer (READY): a randomised, double-blind phase 3 trial

Araujo, J. C., Trudel, G. C., Fred Saad, C., Armstrong, A. J., Yu, E. Y., Joaquim Bellmunt, B., Wilding, G., McCaffrey, J., Serrano, S. V., Matveev, V. B., et al. (2013) · The Lancet Oncology · doi:10.1016/s1470-2045(13)70479-0 · Cited by 231 · see citing works

Structural and Functional Alterations of FLT3 in Acute Myeloid Leukemia

Meshinchi, S., & Appelbaum, F. R. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-1123 · Cited by 224 · see citing works

The dual role of IL-6-type cytokines on bone remodeling and bone tumors

Blanchard, F., Duplomb, L., Baud’huin, M., & Royer, B. B.-L. (2008) · Cytokine & Growth Factor Reviews · doi:10.1016/j.cytogfr.2008.11.004 · Cited by 221 · see citing works

Phase II Study of Dasatinib in Patients with Metastatic Castration-Resistant Prostate Cancer

Yu, E. Y., Wilding, G., Posadas, E. M., Gross, M. E., Culine, S., Massard, C., Morris, M. J., Hudes, G. R., Calabrò, F., Cheng, S., et al. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-09-1691 · Cited by 219 · see citing works

A phase II study of imatinib mesylate in children with refractory or relapsed solid tumors: A Children's Oncology Group study

Bond, M. C., Bernstein, M. L., Pappo, A. S., Schultz, K. R., Krailo, M., Blaney, S. M., & Adamson, P. C. (2007) · Pediatric Blood & Cancer · doi:10.1002/pbc.21132 · Cited by 210 · see citing works

Met induces mammary tumors with diverse histologies and is associated with poor outcome and human basal breast cancer

Ponzo, M. G., Lesurf, R., Petkiewicz, S., O’Malley, F. P., Pinnaduwage, D., Andrulis, I. L., Bull, S. B., Chughtai, N., Zuo, D., Souleimanova, M., et al. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0810402106 · Cited by 204 · see citing works

The product of the protooncogene c-src is modified during the cellular response to platelet-derived growth factor.

Ralston, R., & Bishop, J. M. (1985) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.82.23.7845 · Cited by 203 · see citing works

The gift of Gab

Liu, Y., & Rohrschneider, L. R. (2002) · FEBS Letters · doi:10.1016/s0014-5793(02)02425-0 · Cited by 199 · see citing works

Randomized, Placebo-Controlled, Phase III Trial of Sunitinib Plus Prednisone Versus Prednisone Alone in Progressive, Metastatic, Castration-Resistant Prostate Cancer

Michaelson, M. D., Oudard, S. M., Ou, Y.-C., Sengeløv, L., Fred Saad, C., Houédé, N., Ostler, P. J., Stenzl, A., Daugaard, G., Jones, R. J., et al. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2012.48.5268 · Cited by 194 · see citing works

The Class II cytokine receptor (CRF2) family: overview and patterns of receptor–ligand interactions

Langer, J. A., Cutrone, E. C., & Kotenko, S. V. (2004) · Cytokine & Growth Factor Reviews · doi:10.1016/j.cytogfr.2003.10.001 · Cited by 193 · see citing works

A Phase II Clinical Trial of Sorafenib in Androgen-Independent Prostate Cancer

Dahut, W. L., Scripture, C. D., Posadas, E. M., et al. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-1355 · Cited by 182 · see citing works

Sorafenib blocks tumour growth, angiogenesis and metastatic potential in preclinical models of osteosarcoma through a mechanism potentially involving the inhibition of ERK1/2, MCL-1 and ezrin pathways

Pignochino, Y., Grignani, G., Cavalloni, G., Motta, M., Tapparo, M., Bruno, S., Bottos, A., Gammaitoni, L., Migliardi, G., Camussi, G., et al. (2009) · Molecular Cancer · doi:10.1186/1476-4598-8-118 · Cited by 180 · see citing works

Gefitinib or Placebo in Combination with Tamoxifen in Patients with Hormone Receptor–Positive Metastatic Breast Cancer: A Randomized Phase II Study

Osborne, C. K., Neven, P., Dirix, L. Y., Mackey, J. R., Robert, J., Underhill, C. R., Schiff, R., Gutiérrez, C., Migliaccio, I., Anagnostou, V., et al. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-1869 · Cited by 179 · see citing works

Phase I Pharmacokinetic and Pharmacodynamic Study of Pazopanib in Children With Soft Tissue Sarcoma and Other Refractory Solid Tumors: A Children's Oncology Group Phase I Consortium Report

Bender, J. G., Lee, A., Reid, J. M., et al. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2012.47.0914 · Cited by 168 · see citing works

Bone cell interactions through Eph/ephrin: Bone modeling, remodeling and associated diseases

Matsuo, K., & Otaki, N. (2012) · Cell Adhesion & Migration · doi:10.4161/cam.20888 · Cited by 167 · see citing works

Phase II, Randomized Trial to Compare Anastrozole Combined with Gefitinib or Placebo in Postmenopausal Women with Hormone Receptor–Positive Metastatic Breast Cancer

Cristofanilli, M., Valero, V., Mangalik, A., Royce, M., Rabinowitz, I., Arena, F. P., Kroener, J. F., Curcio, E., Watkins, C. L., Bacus, S. S., et al. (2010) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-09-2282 · Cited by 156 · see citing works

Evolution of Class I cytokine receptors

Liongue, C., & Ward, A. C. (2007) · BMC Evolutionary Biology · doi:10.1186/1471-2148-7-120 · Cited by 150 · see citing works

Negative impact of bone metastasis on outcome in clear-cell renal cell carcinoma treated with sunitinib

Beuselinck, B., Oudard, S. M., Rixe, O., et al. (2010) · Annals of Oncology · doi:10.1093/annonc/mdq554 · Cited by 149 · see citing works

Dysregulation of bone remodeling by imatinib mesylate

Vandyke, K., Fitter, S., Dewar, A. L., Hughes, T. P., & Zannettino, A. C. W. (2009) · Blood · doi:10.1182/blood-2009-08-237404 · Cited by 138 · see citing works

Sunitinib malate for metastatic castration-resistant prostate cancer following docetaxel-based chemotherapy

Sonpavde, G., Periman, P., Bernold, D. M., Weckstein, D. J., Fleming, M. T., Galsky, M. D., Berry, W. R., Zhan, F., Boehm, K. A., Asmar, L., et al. (2009) · Annals of Oncology · doi:10.1093/annonc/mdp323 · Cited by 137 · see citing works

Function of matrix IGF-1 in coupling bone resorption and formation

Crane, J. L., & Cao, X. (2013) · Journal of Molecular Medicine · doi:10.1007/s00109-013-1084-3 · Cited by 133 · see citing works

VEGF and bone cell signalling: an essential vessel for communication?

Clarkin, C., & Gerstenfeld, L. C. (2012) · Cell Biochemistry and Function · doi:10.1002/cbf.2911 · Cited by 130 · see citing works

Small GTP-binding protein-coupled receptors

Bhattacharya, M., Babwah, A. V., & Ferguson, S. S. G. (2004) · Biochemical Society Transactions · doi:10.1042/bst0321040 · Cited by 130 · see citing works

Cabozantinib in Chemotherapy-Pretreated Metastatic Castration-Resistant Prostate Cancer: Results of a Phase II Nonrandomized Expansion Study

Smith, M. R., Sweeney, C. J., Corn, P. G., Rathkopf, D. E., Smith, D. C., Hussain, M., George, D. J., Higano, C. S., Harzstark, A. L., Sartor, O. A., et al. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2013.54.5954 · Cited by 129 · see citing works

An EGF receptor/Ral‐GTPase signaling cascade regulates c‐Src activity and substrate specificity

Goi, T., Shipitsin, M. V., Lu, Z., Foster, D. A., Klinz, S. G., & Feig, L. A. (2000) · The EMBO Journal · doi:10.1093/emboj/19.4.623 · Cited by 129 · see citing works

Platelet-Derived Growth Factor Receptor Inhibitor Imatinib Mesylate and Docetaxel: A Modular Phase I Trial in Androgen-Independent Prostate Cancer

Mathew, P. F., Thall, P. F., JONES, D. M., Perez, C. A., Bucana, C. D., Troncoso, P., Kim, S.-J., Fidler, I. J., & Logothetis, C. J. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.10.116 · Cited by 125 · see citing works

The GIST paradigm: lessons for other kinase‐driven cancers

Antonescu, C. R. (2010) · The Journal of Pathology · doi:10.1002/path.2798 · Cited by 123 · see citing works

Pediatric Phase I Trial and Pharmacokinetic Study of Dasatinib: A Report From the Children's Oncology Group Phase I Consortium

Aplenc, R., Blaney, S. M., Strauss, L. C., Balis, F. M., Shusterman, S., Ingle, A. M., Agrawal, S., Sun, J., Wright, J. J., & Adamson, P. C. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2010.30.7231 · Cited by 122 · see citing works

Final analysis of a phase II trial using sorafenib for metastatic castration‐resistant prostate cancer

Aragon‐Ching, J. B., Jain, L., Gulley, J. L., Arlen, P. M., Wright, J. J., Steinberg, S. M., Draper, D., Venitz, J., Jones, E. C., Chen, C. C., et al. (2009) · British Journal of Urology · doi:10.1111/j.1464-410x.2008.08327.x · Cited by 118 · see citing works

Guanylyl cyclase receptors.

Garbers, D. L., Koesling, D., & Schultz, G. (1994) · Molecular Biology of the Cell · doi:10.1091/mbc.5.1.1 · Cited by 114 · see citing works

Editor's Note: Inhibition of Platelet-derived Growth Factor–mediated Proliferation of Osteosarcoma Cells by the Novel Tyrosine Kinase Inhibitor STI571

McGary, E. C., WEBER, K. L., Mills, L., Doucet, M., Lewis, V., Lev, D. C., Fidler, I. J., & Bar‐Eli, M. (2019) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-19-1101 · Cited by 113 · see citing works

Phase I and Pharmacokinetic Study of Sunitinib in Pediatric Patients with Refractory Solid Tumors: A Children's Oncology Group Study

DuBois, S. G., Shusterman, S., Ingle, A. M., Ahern, C. H., Reid, J. M., Wu, B. H., Baruchel, S., Bender, J. G., Ivy, P. S., Grier, H. E., et al. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-0237 · Cited by 112 · see citing works

Gas6/Axl mediates tumor cell apoptosis, migration and invasion and predicts the clinical outcome of osteosarcoma patients

Han, J., Tian, R., Yong, B., Luo, C., Tan, P., Shen, J., & Peng, T. (2013) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2013.05.019 · Cited by 109 · see citing works

Dasatinib inhibits site-specific tyrosine phosphorylation of androgen receptor by Ack1 and Src kinases.

Liu, Y., Karaca, M., Zhang, Z., Gioeli, D., Earp, H. S., & Whang, Y. E. (2010) · Oncogene · doi:10.1038/onc.2010.103 · Cited by 106 · see citing works

“RAF” neighborhood: Protein–protein interaction in the Raf/Mek/Erk pathway

Cseh, B., Doma, E., & Baccarini, M. (2014) · FEBS Letters · doi:10.1016/j.febslet.2014.06.025 · Cited by 104 · see citing works

Epidermal Growth Factor Receptor (EGFR) mutation analysis, gene expression profiling and EGFR protein expression in primary prostate cancer

Neia, C. P., Migliardi, G., Grand, M. M., et al. (2011) · BMC Cancer · doi:10.1186/1471-2407-11-31 · Cited by 98 · see citing works

Prostate cancer cell–stromal cell crosstalk via FGFR1 mediates antitumor activity of dovitinib in bone metastases

Wan, X., Corn, P. G., Yang, J., Palanisamy, N., Starbuck, M. W., Efstathiou, E., Tapia, E. M. L. N., Zurita, A. J., Aparicio, A. M., Ravoori, M. K., et al. (2014) · Science Translational Medicine · doi:10.1126/scitranslmed.3009332 · Cited by 96 · see citing works

IR/IGF1R signaling as potential target for treatment of high-grade osteosarcoma

Kuijjer, M. L., Peterse, E. F. P., van den Akker, B. E., Bruijn, I. H. B., Serra, M., Meza‐Zepeda, L. A., Myklebost, O., Hassan, A. B., Hogendoorn, P. C. W., & Cleton-Jansen, A. (2013) · BMC Cancer · doi:10.1186/1471-2407-13-245 · Cited by 95 · see citing works

Targeting Platelet-Derived Growth Factor Receptor on Endothelial Cells of Multidrug-Resistant Prostate Cancer

Kim, S.-J., Uehara, H., Yazıcı, S., Busby, J. E., Nakamura, T., He, J., Maya, M., Logothetis, C. J., Mathew, P. F., Wang, X., et al. (2006) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djj211 · Cited by 94 · see citing works

Dasatinib inhibits the growth of prostate cancer in bone and provides additional protection from osteolysis

Koreckij, T. D., Nguyen, H. M., Brown, L. G., Yu, E. Y., Vessella, R. L., & Corey, E. (2009) · British Journal of Cancer · doi:10.1038/sj.bjc.6605178 · Cited by 92 · see citing works

Once-daily Dasatinib: Expansion of Phase II Study Evaluating Safety and Efficacy of Dasatinib in Patients With Metastatic Castration-resistant Prostate Cancer

Yu, E. Y., Massard, C., Gross, M. E., et al. (2011) · Urology · doi:10.1016/j.urology.2011.01.006 · Cited by 91 · see citing works

A phase II study of lapatinib, a dual EGFR and HER-2 tyrosine kinase inhibitor, in patients with castration-resistant prostate cancer

Whang, Y. E., Armstrong, A. J., Rathmell, W. K., Godley, P. A., Kim, W. Y., Pruthi, R. S., Wallen, E., Crane, J. M., Moore, D. T., Grigson, G., et al. (2011) · Urologic Oncology Seminars and Original Investigations · doi:10.1016/j.urolonc.2010.09.018 · Cited by 89 · see citing works

The tyrosine kinase inhibitor dasatinib dysregulates bone remodeling through inhibition of osteoclasts in vivo

Vandyke, K., Dewar, A. L., Diamond, P., Fitter, S., Schultz, C. G., Sims, N. A., & Zannettino, A. C. W. (2010) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.85 · Cited by 89 · see citing works

Platelet-Derived Growth Factor Receptor Inhibition and Chemotherapy for Castration-Resistant Prostate Cancer with Bone Metastases

Mathew, P. F., Thall, P. F., Bucana, C. D., Oh, W. K., Morris, M. J., JONES, D. M., Johnson, M. M., Wen, S., Pagliaro, L. C., Tannir, N. M., et al. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-1269 · Cited by 89 · see citing works

Initial testing (stage 1) of sunitinib by the pediatric preclinical testing program

Maris, J. M., Courtright, J., Houghton, P. J., et al. (2008) · Pediatric Blood & Cancer · doi:10.1002/pbc.21535 · Cited by 85 · see citing works

A phase II trial of docetaxel and erlotinib as first-line therapy for elderly patients with androgen-independent prostate cancer

Gross, M. E., Higano, C. S., Pantuck, A. J., Castellanos, O. O., Green, E., NGUYEN, K. N., & Agus, D. B. (2007) · BMC Cancer · doi:10.1186/1471-2407-7-142 · Cited by 85 · see citing works

Insulin-like growth factor-I receptor tyrosine kinase inhibitor cyclolignan picropodophyllin inhibits proliferation and induces apoptosis in multidrug resistant osteosarcoma cell lines

Duan, Z., Choy, E., Harmon, D. C., Cao, Y., Ryu, K., Schwab, J. H., Mankin, H. J., & Hornicek, F. J. (2009) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-09-0115 · Cited by 84 · see citing works

Metronomic Oral Topotecan with Pazopanib Is an Active Antiangiogenic Regimen in Mouse Models of Aggressive Pediatric Solid Tumor

Kumar, S., Mokhtari, R. B., Sheikh, R., Wu, B. H., Zhang, L., Xu, P., Man, S., Oliveira, I. D., Yeger, H., Kerbel, R. S., et al. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-0078 · Cited by 83 · see citing works

Signaling Pathways Affecting Skeletal Health

Marie, P. J. (2012) · Current Osteoporosis Reports · doi:10.1007/s11914-012-0109-0 · Cited by 81 · see citing works

Protein expression, gene amplification, and mutational analysis of EGFR in triple-negative breast cancer

Nakajima, H., Ishikawa, Y., Furuya, M., et al. (2012) · Breast Cancer · doi:10.1007/s12282-012-0354-1 · Cited by 80 · see citing works

Fibroblast growth factor signaling controlling bone formation: An update

Marie, P. J. (2012) · Gene · doi:10.1016/j.gene.2012.01.086 · Cited by 80 · see citing works

Imatinib Inhibits Proliferation of Ewing Tumor Cells Mediated by the Stem Cell Factor/KIT Receptor Pathway, and Sensitizes Cells to Vincristine and Doxorubicin-Induced Apoptosis

González, I., Andreu, E. J., Panizo, A., et al. (2004) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-0778-03 · Cited by 79 · see citing works

Dasatinib as a Bone-Modifying Agent: Anabolic and Anti-Resorptive Effects

García-Gómez, A., Ocio, E. M., Crusoé, E. D. Q., Santamaría, C., Hernández‐Campo, P. M., Blanco, J. F., Sanchez-Guijo, F. M., Hernández‐Iglesias, T., Briñón, J. G., Fisac-Herrero, R. M., et al. (2012) · PLoS ONE · doi:10.1371/journal.pone.0034914 · Cited by 76 · see citing works

A Multicenter Phase II Clinical Trial of Lapatinib (GW572016) in Hormonally Untreated Advanced Prostate Cancer

Sridhar, S. S., Hotte, S. J., Chin, J. L., et al. (2010) · American Journal of Clinical Oncology · doi:10.1097/coc.0b013e3181beac33 · Cited by 76 · see citing works

CYTOKINES, GROWTH FACTORS AND OSTEOCLASTS

Heymann, D., Guicheux, J., Gouin, F., Passuti, N., & Daculsi, G. (1998) · Cytokine · doi:10.1006/cyto.1997.0277 · Cited by 75 · see citing works

Phase I and Clinical Pharmacology Study of Bevacizumab, Sorafenib, and Low-Dose Cyclophosphamide in Children and Young Adults with Refractory/Recurrent Solid Tumors

Navid, F., Baker, S. D., McCarville, M. B., et al. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-1897 · Cited by 75 · see citing works

Surface proteomic analysis of osteosarcoma identifies EPHA2 as receptor for targeted drug delivery

PosthumaDeBoer, J., Piersma, S. R., Pham, T. V., van Egmond, P. W., Knol, J. C., Cleton-Jansen, A. M., van Geer, M. A., van Beusechem, V. W., Kaspers, G. J. L., van Royen, B. J., et al. (2013) · British Journal of Cancer · doi:10.1038/bjc.2013.578 · Cited by 73 · see citing works

A Dose-Ranging Study of Cabozantinib in Men with Castration-Resistant Prostate Cancer and Bone Metastases

Lee, R. J., Saylor, P. J., Michaelson, M. D., et al. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-0319 · Cited by 73 · see citing works

Preclinical Evaluation of Imaging Biomarkers for Prostate Cancer Bone Metastasis and Response to Cabozantinib

Graham, T. J., Box, G., Tunariu, N., et al. (2014) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/dju033 · Cited by 72 · see citing works

The Bone Niche of Chondrosarcoma: A Sanctuary for Drug Resistance, Tumour Growth and also a Source of New Therapeutic Targets

David, E., Blanchard, F., Heymann, M., Pinieux, G. D. B. D., Gouin, F., Rédiní, F., & Heymann, D. (2011) · Sarcoma · doi:10.1155/2011/932451 · Cited by 70 · see citing works

Phase I dose escalation and pharmacokinetic study of AZD2171, an inhibitor of the vascular endothelial growth factor receptor tyrosine kinase, in patients with hormone refractory prostate cancer (HRPC)

Ryan, C. J., Stadler, W. M., Roth, B. J., et al. (2007) · Investigational New Drugs · doi:10.1007/s10637-007-9050-y · Cited by 70 · see citing works

<i>De novo</i> expression of EphA2 in osteosarcoma modulates activation of the mitogenic signalling pathway

Fritsche‐Guenther, R., Noske, A., Ungethüm, U., Kuban, R., Schlag, P. M., Tunn, P., Karle, J., Krenn, V., Dietel, M., & Sers, C. (2010) · Histopathology · doi:10.1111/j.1365-2559.2010.03713.x · Cited by 69 · see citing works

Cabozantinib Inhibits Growth of Androgen-Sensitive and Castration-Resistant Prostate Cancer and Affects Bone Remodeling

Nguyen, H. M., Ruppender, N. S., Zhang, X., et al. (2013) · PLoS ONE · doi:10.1371/journal.pone.0078881 · Cited by 69 · see citing works

Inhibition of Src Phosphorylation Alters Metastatic Potential of Osteosarcoma In vitro but not In vivo

Hingorani, P., Zhang, W., Gorlick, R. G., & Kolb, E. A. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-1657 · Cited by 68 · see citing works

Imatinib mesylate (Gleevec®) enhances mature osteoclast apoptosis and suppresses osteoclast bone resorbing activity

Dib, I. E. H., Gallet, M., Mentaverri, R., et al. (2006) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2006.09.007 · Cited by 61 · see citing works

Expression and clinical relevance of MET and ALK in Ewing sarcomas

Fleuren, E. D. G., Roeffen, M. H. S., Leenders, W. P. J., et al. (2013) · International Journal of Cancer · doi:10.1002/ijc.28047 · Cited by 60 · see citing works

Targeted inhibition of the epidermal growth factor receptor‐tyrosine kinase by ZD1839 (‘Iressa’) induces cell‐cycle arrest and inhibits proliferation in prostate cancer cells

Sgambato, A., Camerini, A., Faraglia, B., et al. (2004) · Journal of Cellular Physiology · doi:10.1002/jcp.20045 · Cited by 59 · see citing works

Breast Cancer–Derived Bone Metastasis Can Be Effectively Reduced through Specific c-MET Inhibitor Tivantinib (ARQ 197) and shRNA c-MET Knockdown

Previdi, S., Abbadessa, G., Dalò, F., et al. (2011) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-11-0277 · Cited by 58 · see citing works

Structural aspects of oligomerization taking place between the transmembrane α-helices of bitopic membrane proteins

Arkin, I. T. (2002) · Biochimica et Biophysica Acta (BBA) - Biomembranes · doi:10.1016/s0005-2736(02)00580-1 · Cited by 57 · see citing works

Erlotinib Has Moderate Single-agent Activity in Chemotherapy-naïve Castration-resistant Prostate Cancer: Final Results of a Phase II Trial

Nabhan, C., Lestingi, T. M., Galvez, A. G., Tolzien, K., Kelby, S. K., Tsarwhas, D., Newman, S. B., & Bitran, J. D. (2009) · Urology · doi:10.1016/j.urology.2009.05.016 · Cited by 56 · see citing works

Hepatocyte growth factor/scatter factor expression and c-met in primary breast cancer

Nagy, J., Curry, G., Hillan, K. J., McKay, I. C., Mallon, E., Purushotham, A. D., & George, W. D. (1996) · Surgical Oncology · doi:10.1016/s0960-7404(96)80017-x · Cited by 55 · see citing works

Phase II clinical trial of imatinib mesylate in therapy of KIT and/or PDGFRalpha-expressing Ewing sarcoma family of tumors and desmoplastic small round cell tumors.

Chao, J., Budd, G. T., Chu, P. G., et al. (2010) · PubMed · Cited by 55 · see citing works

Bisphosphonates combined with sunitinib may improve the response rate, progression free survival and overall survival of patients with bone metastases from renal cell carcinoma

Keizman, D., Ish‐Shalom, M., Пили, Р., et al. (2012) · European Journal of Cancer · doi:10.1016/j.ejca.2012.02.050 · Cited by 54 · see citing works

Dancing with the dead: Eph receptors and their kinase-null partnersThis paper is one of a selection of papers published in a Special Issue entitled CSBMCB 53rd Annual Meeting — Membrane Proteins in Health and Disease, and has undergone the Journal’s usual peer review process.

Truitt, L., & Freywald, A. (2011) · Biochemistry and Cell Biology · doi:10.1139/o10-145 · Cited by 54 · see citing works

Autoinhibitory mechanisms in receptor tyrosine kinases

Hubbard, S. R. (2002) · Frontiers in bioscience · doi:10.2741/a778 · Cited by 51 · see citing works

Erlotinib inhibits osteolytic bone invasion of human non-small-cell lung cancer cell line NCI-H292

Furugaki, K., Moriya, Y., Iwai, T., Yorozu, K., Yanagisawa, M., Kondoh, K., Fujimoto-Ouchi, K., & Mori, K. (2011) · Clinical & Experimental Metastasis · doi:10.1007/s10585-011-9398-4 · Cited by 51 · see citing works

An Open-Label, Single-Arm Phase Two Trial of Gefitinib in Patients With Advanced or Metastatic Castration-Resistant Prostate Cancer

Pezaro, C. J., Rosenthal, M. A., Gurney, H., Davis, I. D., Underhill, C. R., Boyer, M. J., Kotasek, D., Solomon, B., & Toner, G. C. (2009) · American Journal of Clinical Oncology · doi:10.1097/coc.0b013e31818b946b · Cited by 51 · see citing works

The orally bioavailable met inhibitor PF-2341066 inhibits osteosarcoma growth and osteolysis/matrix production in a xenograft model

Sampson, E. R., Martin, B., Morris, A. E., et al. (2011) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.336 · Cited by 50 · see citing works

Imatinib Mesylate Exerts Anti-Proliferative Effects on Osteosarcoma Cells and Inhibits the Tumour Growth in Immunocompetent Murine Models

Gobin, B., Moriceau, G., Ory, B., Charrier, C., Brion, R., Blanchard, F., Rédiní, F., & Heymann, D. (2014) · PLoS ONE · doi:10.1371/journal.pone.0090795 · Cited by 49 · see citing works

Cediranib/AZD2171 Inhibits Bone and Brain Metastasis in a Preclinical Model of Advanced Prostate Cancer

Yin, J. J., Zhang, L., Munasinghe, J., Linnoila, R. I., & Kelly, K. (2010) · Cancer Research · doi:10.1158/0008-5472.can-10-1435 · Cited by 48 · see citing works

The role of AXL and the in vitro activity of the receptor tyrosine kinase inhibitor BGB324 in Ewing sarcoma

Fleuren, E. D. G., Hillebrandt-Roeffen, M. H. S., Flucke, U. E., Loo, D. M. W. M. T., Boerman, O. C., van der Graaf, W. T. A., & Versleijen‐Jonkers, Y. M. H. (2014) · Oncotarget · doi:10.18632/oncotarget.2648 · Cited by 47 · see citing works

Importance of Wnt Signaling in the Tumor Stroma Microenvironment

Macheda, M. L., & Stacker, S. A. (2008) · Current Cancer Drug Targets · doi:10.2174/156800908785699324 · Cited by 47 · see citing works

Dasatinib inhibits both osteoclast activation and prostate cancer PC-3 cell-induced osteoclast formation

Araujo, J. C., Poblenz, A. T., Parikh, N. U., Starbuck, M. W., Thompson, J. T., Lee, F. Y., Logothetis, C. J., & Darnay, B. G. (2009) · Cancer Biology & Therapy · doi:10.4161/cbt.8.22.9770 · Cited by 46 · see citing works

Insulin-Like Growth Factor 1 Receptor and Response to Anti-IGF1R Antibody Therapy in Osteosarcoma

Cao, Y., Roth, M. E., Piperdi, S., Montoya, K., Sowers, R. S., Rao, P. H., Geller, D., Houghton, P. J., Kolb, E. A., Gill, J. B., et al. (2014) · PLoS ONE · doi:10.1371/journal.pone.0106249 · Cited by 45 · see citing works

The skeletal effects of the tyrosine kinase inhibitor nilotinib

O’Sullivan, S., Lin, J., Watson, M., Callon, K. E., Tong, P. C., Naot, D., Horne, A. M., Aati, O., Porteous, F., Gamble, G. D., et al. (2011) · Bone · doi:10.1016/j.bone.2011.04.014 · Cited by 45 · see citing works

Randomised, phase II, placebo-controlled, trial of fulvestrant plus vandetanib in postmenopausal women with bone only or bone predominant, hormone-receptor-positive metastatic breast cancer (MBC): the OCOG ZAMBONEY study

Clemons, M. J., Cochrane, B., Pond, G. R., Califaretti, N., Chia, S., Dent, R. A., Song, X., Robidoux, A., Parpia, S., Warr, D. G., et al. (2014) · Breast Cancer Research and Treatment · doi:10.1007/s10549-014-3015-6 · Cited by 45 · see citing works

Sorafenib tosylate and paclitaxel induce anti-angiogenic, anti-tumour and anti-resorptive effects in experimental breast cancer bone metastases

Merz, M., Komljenovic, D., Zwick, S., Semmler, W., & Bäuerle, T. (2010) · European Journal of Cancer · doi:10.1016/j.ejca.2010.08.019 · Cited by 45 · see citing works

Effects of Cabozantinib on Pain and Narcotic Use in Patients with Castration-resistant Prostate Cancer: Results from a Phase 2 Nonrandomized Expansion Cohort

Basch, E., Autio, K. A., Smith, M. R., Bennett, A. V., Weitzman, A., Scheffold, C., Sweeney, C. J., Rathkopf, D. E., Smith, D. C., George, D. J., et al. (2014) · European Urology · doi:10.1016/j.eururo.2014.02.013 · Cited by 43 · see citing works

Ligand-gated ion channel interacting proteins and their role in neuroprotection

Li, S., Wong, A. H. C., & Liu, F. (2014) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2014.00125 · Cited by 43 · see citing works

Effects of the combined blockade of EGFR and ErbB-2 on signal transduction and regulation of cell cycle regulatory proteins in breast cancer cells

D’Alessio, A., Luca, A. D., Maiello, M. R., et al. (2009) · Breast Cancer Research and Treatment · doi:10.1007/s10549-009-0649-x · Cited by 43 · see citing works

In vitro antiproliferative and antimigratory activity of dasatinib in neuroblastoma and Ewing sarcoma cell lines

Timeus, F. S., Crescenzio, N., Fandi, A., et al. (2008) · Oncology Reports · doi:10.3892/or.19.2.353 · Cited by 42 · see citing works

Targeted therapies for bone sarcomas

Heymann, D., & Rédiní, F. (2013) · BoneKEy Reports · doi:10.1038/bonekey.2013.112 · Cited by 42 · see citing works

An Open-Label, Noncomparative Phase II Trial to Evaluate the Efficacy and Safety of Docetaxel in Combination with Gefitinib in Patients with Hormone-Refractory Metastatic Prostate Cancer

Salzberg, M. O., Rochlitz, C. F., Morant, R., et al. (2007) · Oncology Research and Treatment · doi:10.1159/000102452 · Cited by 42 · see citing works

Epidermal Growth Factor Receptor: Is It a Feasible Target for the Treatment of Osteosarcoma?

Lee, J. A., Ko, Y., Kim, D. H., Lim, J. S., Kong, C., Cho, W. H., Jeon, D., Lee, S., & Koh, J.-S. (2012) · Cancer Research and Treatment · doi:10.4143/crt.2012.44.3.202 · Cited by 41 · see citing works

A randomized trial of combination anastrozole plus gefitinib and of combination fulvestrant plus gefitinib in the treatment of postmenopausal women with hormone receptor positive metastatic breast cancer

Carlson, R. W., O’Neill, A., Vidaurre, T., et al. (2012) · Breast Cancer Research and Treatment · doi:10.1007/s10549-012-1997-5 · Cited by 41 · see citing works

Initial testing of the multitargeted kinase inhibitor pazopanib by the pediatric preclinical testing program

Keir, S. T., Morton, C. L., Wu, J., et al. (2011) · Pediatric Blood & Cancer · doi:10.1002/pbc.24016 · Cited by 37 · see citing works

Imatinib mesylate and zoledronic acid in androgen-independent prostate cancer

Tiffany, N. M., Wersinger, E. M., Garzotto, M. G., et al. (2004) · Urology · doi:10.1016/j.urology.2003.12.022 · Cited by 36 · see citing works

Gefitinib inhibits the cross‐talk between mesenchymal stem cells and prostate cancer cells leading to tumor cell proliferation and inhibition of docetaxel activity

Borghese, C., Cattaruzza, L., Pivetta, E., Normanno, N., Luca, A. D., Mazzucato, M., Celegato, M., Colombatti, A., & Aldinucci, D. (2012) · Journal of Cellular Biochemistry · doi:10.1002/jcb.24456 · Cited by 35 · see citing works

A randomized phase II efficacy and safety study of vandetanib (ZD6474) in combination with bicalutamide versus bicalutamide alone in patients with chemotherapy naïve castration-resistant prostate cancer

Azad, A., Beardsley, E. K., Hotte, S. J., et al. (2014) · Investigational New Drugs · doi:10.1007/s10637-014-0091-8 · Cited by 33 · see citing works

Addition of receptor tyrosine kinase inhibitor to radiation increases tumour control in an orthotopic murine model of breast cancer metastasis in bone

Zwolak, P., Jasiński, P., Terai, K., et al. (2008) · European Journal of Cancer · doi:10.1016/j.ejca.2008.07.011 · Cited by 32 · see citing works

Receptor Tyrosine Kinases in Osteosarcoma: Not Just the Usual Suspects

Rettew, A. N., Getty, P. J., & Greenfield, E. M. (2014) · Advances in experimental medicine and biology · doi:10.1007/978-3-319-04843-7_3 · Cited by 30 · see citing works

Knockdown of AXL Receptor Tyrosine Kinase in Osteosarcoma Cells Leads to Decreased Proliferation and Increased Apoptosis

Zhang, Y., Tang, Y.-J., Man, Y., Pan, F., Li, Z.-H., & Jia, L.-S. (2013) · International Journal of Immunopathology and Pharmacology · doi:10.1177/039463201302600117 · Cited by 30 · see citing works

The role of the insulin-like growth factor (IGF) axis in osteogenic and odontogenic differentiation

Alkharobi, H. E., El-Gendy, R., DeVine, D., et al. (2013) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-013-1508-9 · Cited by 29 · see citing works

Combination of anti‐angiogenic therapies reduces osteolysis and tumor burden in experimental breast cancer bone metastasis

Bachelier, R., Confavreux, C. B., Peyruchaud, O., Croset, M., Goehrig, D., van der Pluijm, G., & Clézardin, P. (2014) · International Journal of Cancer · doi:10.1002/ijc.28787 · Cited by 28 · see citing works

Sunitinib in combination with trastuzumab for the treatment of advanced breast cancer: activity and safety results from a phase II study

Bachelot, T., García-Sáenz, J. Á., Verma, S., et al. (2014) · BMC Cancer · doi:10.1186/1471-2407-14-166 · Cited by 27 · see citing works

Receptor tyrosine kinase signaling mechanisms: Devolving TrkA responses with phosphoproteomics

Bradshaw, R. A., Chalkley, R. J., Biarc, J., et al. (2012) · Advances in Biological Regulation · doi:10.1016/j.jbior.2012.10.006 · Cited by 27 · see citing works

Bone Sarcomas: From Biology to Targeted Therapies

Gaspar, N., Giannatale, A. D., Geoerger, B., Rédiní, F., Corradini, N., Entz‐Werlé, N., Tirode, F., Marec‐Bérard, P., Gentet, J., Laurence, V., et al. (2012) · Sarcoma · doi:10.1155/2012/301975 · Cited by 27 · see citing works

Prednisone plus Gefitinib versus Prednisone plus Placebo in the Treatment of Hormone-Refractory Prostate Cancer: A Randomized Phase II Trial

Boccardo, F., RUBAGOTTI, A., Conti, G. N., et al. (2008) · Oncology · doi:10.1159/000151391 · Cited by 25 · see citing works

Trk receptor inhibition induces apoptosis of proliferating but not quiescent human osteoblasts.

Pinski, J., Weeraratna, A. T., Uzgare, A. R., et al. (2002) · PubMed · Cited by 25 · see citing works

Phase I study of dasatinib (BMS‐354825) in Japanese patients with solid tumors

Takahashi, S., Miyazaki, M., Okamoto, I., Ito, Y., Ueda, K., Seriu, T., Nakagawa, K., & Hatake, K. (2011) · Cancer Science · doi:10.1111/j.1349-7006.2011.02041.x · Cited by 24 · see citing works

A phase I/II prospective, single arm trial of gefitinib, trastuzumab, and docetaxel in patients with stage IV HER-2 positive metastatic breast cancer

Somlo, G., Martel, C. L., Lau, S. K., Frankel, P. H., Ruel, C., Gu, L., Hurria, A., Chung, C. T., Luu, T., Morgan, R. J., et al. (2011) · Breast Cancer Research and Treatment · doi:10.1007/s10549-011-1850-2 · Cited by 24 · see citing works

Autoinhibitory mechanisms in receptor tyrosine kinases

Stevan, R. H. (2002) · Frontiers in bioscience · doi:10.2741/hubbard · Cited by 24 · see citing works

Bone sarcomas: pathogenesis and new therapeutic approaches

Heymann, D., & Rédiní, F. (2011) · IBMS BoneKEy · doi:10.1138/20110531 · Cited by 23 · see citing works

ABT-869 Inhibits the Proliferation of Ewing Sarcoma Cells and Suppresses Platelet-Derived Growth Factor Receptor β and c-KIT Signaling Pathways

Ikeda, A. K., Judelson, D. R., Federman, N. C., et al. (2010) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-09-0812 · Cited by 20 · see citing works

Oncogenic activation of the PDGF β receptor by the transmembrane domain of p185neu*

Petti, L. M., Irusta, P. M., & DiMaio, D. (1998) · Oncogene · doi:10.1038/sj.onc.1201590 · Cited by 20 · see citing works

Combination of the c-Met Inhibitor Tivantinib and Zoledronic Acid Prevents Tumor Bone Engraftment and Inhibits Progression of Established Bone Metastases in a Breast Xenograft Model

Previdi, S., Scolari, F., Chilà, R., et al. (2013) · PLoS ONE · doi:10.1371/journal.pone.0079101 · Cited by 17 · see citing works

HER-2 Involvement in Osteosarcoma

Gill, J. B., Geller, D., & Gorlick, R. G. (2014) · Advances in experimental medicine and biology · doi:10.1007/978-3-319-04843-7_9 · Cited by 15 · see citing works

Mutation status of somatic EGFR and KRAS genes in Chinese patients with prostate cancer (PCa)

Fu, M., Zhang, Y., Shan, L., et al. (2014) · Archiv für Pathologische Anatomie und Physiologie und für Klinische Medicin · doi:10.1007/s00428-014-1566-x · Cited by 15 · see citing works

Managing GIST in the imatinib era: optimization of adjuvant therapy

Trent, J. C., & Subramanian, M. (2014) · Expert Review of Anticancer Therapy · doi:10.1586/14737140.2014.952284 · Cited by 14 · see citing works

Lapatinib-plus-pegylated liposomal doxorubicin in advanced HER2-positive breast cancer following trastuzumab: a phase II trial.

Pircher, M., Mlineritsch, B., Fridrik, M., et al. (2015) · PubMed · Cited by 13 · see citing works

The prostate cancer blocking potential of the histone deacetylase inhibitor LBH589 is not enhanced by the multi receptor tyrosine kinase inhibitor TKI258

Vallo, S., Mani, J., Stastny, M., Makarević, J., Juengel, E., Tsaur, I., Bartsch, G. C., Haferkamp, A., & Blaheta, R. A. (2012) · Investigational New Drugs · doi:10.1007/s10637-012-9851-5 · Cited by 11 · see citing works

Cabozantinib and Prostate Cancer: Inhibiting Seed and Disrupting Soil?

Lee, R. J., & Smith, M. R. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-2636 · Cited by 10 · see citing works

Adjuvant Therapy with Sorafenib in Bone Metastases Bilateral Renal Carcinoma: A Case Report

Sciarra, A., Gomez, A. M. A., Gentilucci, A., et al. (2007) · European Urology · doi:10.1016/j.eururo.2007.03.083 · Cited by 8 · see citing works

Systematic screen with kinases inhibitors reveals kinases play distinct roles in growth of osteoprogenitor cells.

Bao, N., Lü, M., Bin, F.-W., Chang, Z.-Y., Meng, J., Zhou, L., Guo, T., & Zhao, J.-N. (2013) · Europe PMC (PubMed Central) · Cited by 6 · see citing works

Physiopathologie des métastases osseuses et nouvelles cibles moléculaires impliquées dans le remodelage osseux

Clézardin, P. (2013) · Bulletin du Cancer · doi:10.1684/bdc.2013.1836 · Cited by 5 · see citing works

Sorafenib inhibits in vitro osteoclastogenesis by down-modulating Mcl-1

Rimondi, E., Secchiero, P., Melloni, E., et al. (2012) · Investigational New Drugs · doi:10.1007/s10637-012-9903-x · Cited by 2 · see citing works

Osteosarcoma

Beird, H. C., Bielack, S. S., Flanagan, A. M., Gill, J., Heymann, D., Janeway, K. A., Livingston, J. A., Roberts, R. D., Strauss, S. J., & Gorlick, R. (2022) · Nature Reviews Disease Primers · doi:10.1038/s41572-022-00409-y · Cited by 660 · see citing works

Biology of Bone Sarcomas and New Therapeutic Developments

Brown, H. K., Schiavone, K., Gouin, F., Heymann, M.-F., & Heymann, D. (2018) · Calcified Tissue International · doi:10.1007/s00223-017-0372-2 · Cited by 163 · see citing works

Efficacy of imatinib mesylate (STI571) in chronic neutrophilic leukemia with t(15;19): Case report

Choi, I. K., Kim, B., Lee, K., et al. (2004) · American Journal of Hematology · doi:10.1002/ajh.20197 · Cited by 15 · see citing works

Quantitative approaches to analyzing imatinib-treated chronic myeloid leukemia

Franziska Michor, A. (2007) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2007.03.003 · Cited by 26 · see citing works

Simultaneously occurring chronic myelogenous leukemia and gastrointestinal stromal tumors treated with imatinib

Mishima, Y., Terui, Y., Takeuchi, K., et al. (2006) · Targeted Oncology · doi:10.1007/s11523-006-0021-6

Molecular Monitoring of Chronic Myeloid Leukemia Treated with Imatinib Mesylate

Wei, Y. (2007) · Gothenburg University Publications Electronic Archive (Gothenburg University)

Response assessment of patients with chronic myeloid leukemia receiving imatinib mesylate (Glivec) therapy: experience from a single center in a developing country

Medhi, K., Raina, V., Kumar, L., et al. (2010) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.3109/10428194.2010.507416 · Cited by 10 · see citing works